Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 15;20(3):602–611. doi: 10.1158/1535-7163.MCT-20-0412

Figure 2.

Figure 2.

Treatment with anti-TGF-β monoclonal antibody in the ID8-p53−/− tumor model. (A) Schema of treatment dosing. (B) Ascites volume is significantly reduced following treatment with anti-TGF-β antibody. (C) Omental weights are similar between treated and untreated mice. (D-F) Favorable changes in T-cell response – (D) trending increase in proportion of CD8 T cells, (E) decrease in Tregs and (F) increased in CD8:Treg ratio, occur following treatment. (* p < 0.05, *** p < 0.001, ns - non-significant, bars represent SEM; dotted line – mean weight of naïve mouse omentum).